John Spence, MD
Undersea and Hyperbaric Medicine · Vidalia, GANPI 1124034996
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $490 of the $569 with a category attached, or 86.0%. 9 manufacturers reported payments, led by Organogenesis Inc. at 27.3% of the total. Reporting peaked in 2019 at $197 and has fallen 63.3% since, to $72 in 2025.
Across 23 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$155
- AbbVie$80
- Acera Surgical, Inc.$65
- Smith+Nephew$61
- Abiomed$58
- Integra Lifesciences Corporation$50
- plus $100 from 3 others
What the payments were for
- Speaking & faculty fees$8014%
- Food & beverage$49086%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 4 | $155 |
| AbbVie(2 entities) | 6 | $80 |
| Acera Surgical, Inc. | 1 | $65 |
| Smith+Nephew | 5 | $61 |
| Abiomed | 1 | $58 |
| Integra Lifesciences Corporation | 1 | $50 |
| Kerecis Limited | 2 | $37 |
| Aroa Biosurgery Incorporated | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $27 |
How this compares
Too few undersea and hyperbaric medicine providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 82 | $1,184 |
| Liothyronine Sodium | 31 | $864 |
| Doxycycline Monohydrate | 68 | $695 |
| Ampicillin Trihydrate | 24 | $281 |
| Doxycycline Hyclate | 25 | $242 |
| Ciprofloxacin Hcl | 29 | $134 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $127 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $100 |
| Clindamycin Hcl | 16 | $86 |
| Anastrozole | 11 | $52 |
| Finasteride | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other undersea and hyperbaric medicine in Vidalia
- Belinda MarcusNewnan$26K
- Dana ConnerBlairsville$4K
- Norman McCullochWinder$2K
- Ricardo DuranRoswell$2K
- William LagalyAthens$2K
- Jose GomezCalhoun$1K
- Daniel BelessSandy Springs$955
- John McGlynnMarietta$456
- Helen GellyMarietta$439
- Martin LynchRome$419
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.